Targeting Immune System Alterations in Hodgkin Lymphoma.
Targeting Immune System Alterations in Hodgkin Lymphoma.
复制标题
DOI：
10.1007/s11899-017-0398-6
复制
发表时间：
2017-08
影响因子：
2.9
通讯作者：
Savoldo B
中科院分区：
文献类型：
--
作者：
Grover NS;Savoldo B
This review discusses novel immunotherapeutic approaches to treat Hodgkin lymphoma (HL), specifically PD-1 inhibitors and cellular immunotherapy. PD-1 inhibitors have shown promising results in the treatment of relapsed or refractory HL, leading to FDA approval of nivolumab and pembrolizumab, although complete remissions are rare. Chimeric antigen receptor T cells directed against CD30 have been investigated with preliminary clinical trials showing minimal toxicities and some responses in heavily pre-treated patients with HL. HL is unique as it consists of a small percentage of malignant cells (Hodgkin Reed Sternberg cells) surrounded by an inflammatory microenvironment which promotes tumor growth and suppresses immune responses, making it an ideal target for immunotherapeutic approaches, such as PD-1 inhibitors and cellular immunotherapy. Current research is focused on overcoming barriers to efficacy via rational combinations that overcome resistance to therapy.
登录
查看更多内容
T细胞共刺激和共抑制的分子机制。
DOI：
10.1038/nri3405
发表时间：
2013-04
期刊：
Nature reviews. Immunology
影响因子：
--
作者：
通讯作者：
--
影响因子：
20.3
作者：
Evens, Andrew M.;Helenowski, Irene;Smith, Sonali M.
通讯作者：
Smith, Sonali M.
DOI：
10.1158/1078-0432.ccr-13-0855
发表时间：
2013-07-01
期刊：
Clinical cancer research : an official journal of the American Association for Cancer Research
影响因子：
--
作者：
Chen BJ;Chapuy B;Ouyang J;Sun HH;Roemer MG;Xu ML;Yu H;Fletcher CD;Freeman GJ;Shipp MA;Rodig SJ
通讯作者：
Rodig SJ
影响因子：
20.3
作者：
Chen, Robert;Gopal, Ajay K.;Younes, Anas
通讯作者：
Younes, Anas
影响因子：
20.3
作者：
Bollard, Catherine M.;Gottschalk, Stephen;Heslop, Helen E.
通讯作者：
Heslop, Helen E.